Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tim Spelman

Showing results (131-140 of 266) with videos related to

Pageof 27
Sort By:
Therapeutic Advances in Neurological Disorders|October 4, 2021
No evidence for loss of natalizumab effectiveness with every-6-week dosing: a propensity score-matched comparison with every-4-week dosing in patients enrolled in the Tysabri Observational Program (TOP)Helmut Butzkueven, Ludwig Kappos, Tim Spelman, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|April 3, 2020
Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP)Helmut Butzkueven, Ludwig Kappos, Heinz Wiendl, et al.
Journal of Clinical Microbiology|November 4, 2016
Optimal Periprosthetic Tissue Specimen Number for Diagnosis of Prosthetic Joint InfectionTrisha N Peel, Tim Spelman, Brenda L Dylla, et al.
Haematologica|November 8, 2011
Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute myeloid leukemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year periodMichelle R Ananda-Rajah, Andrew Grigg, Maria T Downey, et al.
Sexual Health|May 20, 2011
Impact evaluation of a youth sexually transmissible infection awareness campaign using routinely collected data sourcesJudy Gold, Jane Goller, Margaret Hellard, et al.
Frontiers in Immunology|October 21, 2017
Predicting Risk of Infection in Patients with Newly Diagnosed Multiple Myeloma: Utility of Immune ProfilingBenjamin W Teh, Simon J Harrison, Cody Charles Allison, et al.
Current Neuropharmacology|March 25, 2026
Ocrelizumab Discontinuation vs. Continuation After Safety Events: Comparative Insights from MSBaseAurora Zanghì, Tim Spelman, Marzena Fabis-Pedrini, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|April 16, 2020
Burden and clinical outcomes of hospital-coded infections in patients with cancer: an 11-year longitudinal cohort study at an Australian cancer centreJake C Valentine, Lisa Hall, Tim Spelman, et al.
The Australian and New Zealand Journal of Psychiatry|May 27, 2023
Childhood trauma is prevalent and associated with co-occurring depression, anxiety, mania and psychosis in young people attending Australian youth mental health servicesSarah Bendall, Oliver Eastwood, Tim Spelman, et al.
Plos One|August 23, 2013
Predictors of raised viral load during antiretroviral therapy in patients with and without prior antiretroviral use: a cross-sectional studyJane E Greig, Philipp A du Cros, Clair Mills, et al.
Pageof 27

Showing results (131-140 of 266) with videos related to

Sort By:
Pageof 27
Therapeutic Advances in Neurological Disorders|October 4, 2021
No evidence for loss of natalizumab effectiveness with every-6-week dosing: a propensity score-matched comparison with every-4-week dosing in patients enrolled in the Tysabri Observational Program (TOP)Helmut Butzkueven, Ludwig Kappos, Tim Spelman, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|April 3, 2020
Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP)Helmut Butzkueven, Ludwig Kappos, Heinz Wiendl, et al.
Journal of Clinical Microbiology|November 4, 2016
Optimal Periprosthetic Tissue Specimen Number for Diagnosis of Prosthetic Joint InfectionTrisha N Peel, Tim Spelman, Brenda L Dylla, et al.
Haematologica|November 8, 2011
Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute myeloid leukemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year periodMichelle R Ananda-Rajah, Andrew Grigg, Maria T Downey, et al.
Sexual Health|May 20, 2011
Impact evaluation of a youth sexually transmissible infection awareness campaign using routinely collected data sourcesJudy Gold, Jane Goller, Margaret Hellard, et al.
Frontiers in Immunology|October 21, 2017
Predicting Risk of Infection in Patients with Newly Diagnosed Multiple Myeloma: Utility of Immune ProfilingBenjamin W Teh, Simon J Harrison, Cody Charles Allison, et al.
Current Neuropharmacology|March 25, 2026
Ocrelizumab Discontinuation vs. Continuation After Safety Events: Comparative Insights from MSBaseAurora Zanghì, Tim Spelman, Marzena Fabis-Pedrini, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|April 16, 2020
Burden and clinical outcomes of hospital-coded infections in patients with cancer: an 11-year longitudinal cohort study at an Australian cancer centreJake C Valentine, Lisa Hall, Tim Spelman, et al.
The Australian and New Zealand Journal of Psychiatry|May 27, 2023
Childhood trauma is prevalent and associated with co-occurring depression, anxiety, mania and psychosis in young people attending Australian youth mental health servicesSarah Bendall, Oliver Eastwood, Tim Spelman, et al.
Plos One|August 23, 2013
Predictors of raised viral load during antiretroviral therapy in patients with and without prior antiretroviral use: a cross-sectional studyJane E Greig, Philipp A du Cros, Clair Mills, et al.
Pageof 27